Scholarlink

<p>Patients with multiple ipsilateral renal tumors face an increased risk of recurrence, making nephron-sparing surgery (NSS) essential to preserve renal function. Due to their technical complexity, these procedures have traditionally been performed via open partial nephrectomy (OPN). This study aimed to compare perioperative, functional, and oncologic outcomes of robot-assisted partial nephrectomy (RAPN) versus OPN in this challenging setting. We conducted a retrospective analysis of prospectively collected data from 20 centers of the French national kidney cancer research network UroCCR (NCT03293563; CNIL DR-2022-091). The primary endpoint was perioperative morbidity, assessed using the Clavien–Dindo classification. Secondary outcomes included Trifecta achievement, renal functional outcomes (pre- and 3-month postoperative eGFR, new-onset CKD, and AKI), and oncologic outcomes (disease-free survival [DFS], and overall survival [OS]). Overall, 212 patients underwent NSS for multiple ipsilateral renal tumors between June 2007 and July 2025 (146 RAPN, 66 OPN). After 1:1 matching for BMI, ASA score, and indication for NSS, 132 patients were analyzed (66 per group). RAPN was associated with shorter hospitalization (3.2 vs. 7.7 days, <i>p</i> &lt; 0.001), fewer complications (6.1% vs. 21.2%, <i>p</i> = 0.02), and less frequent main renal artery clamping (51.5% vs. 86.4%, <i>p</i> &lt; 0.001), despite longer operative and clamping times. Trifecta rates (50.8% vs. 61.9%, <i>p</i> = 0.29) and renal function at 3 months were comparable. At a median follow-up of 30.7 months, DFS and OS did not differ significantly between groups (<i>p</i> = 0.69). RAPN is a safe and effective alternative to OPN for multiple ipsilateral renal tumors, providing comparable oncologic and functional outcomes with reduced morbidity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Robot-assisted versus open surgery for multiple ipsilateral renal tumors: a multicenter matched cohort study (UroCCR-60)

  • 期刊论文

  • 发表日期：

    2026年3月9日

查看全文
  • Gaëlle Margue,
  • Candice Debard,
  • Clément Klein,
  • Nicolas Doumerc,
  • Karim Bensalah,
  • Charles Dariane,
  • Franck Bruyere,
  • Jérome Rizk,
  • Cédric Lebacle,
  • Pierre Bigot,
  • Alexandre De la Taille,
  • Hervé Lang,
  • Arnaud Mejean,
  • Morgan Roupret,
  • Jean-Christophe Bernhard

摘要

Patients with multiple ipsilateral renal tumors face an increased risk of recurrence, making nephron-sparing surgery (NSS) essential to preserve renal function. Due to their technical complexity, these procedures have traditionally been performed via open partial nephrectomy (OPN). This study aimed to compare perioperative, functional, and oncologic outcomes of robot-assisted partial nephrectomy (RAPN) versus OPN in this challenging setting. We conducted a retrospective analysis of prospectively collected data from 20 centers of the French national kidney cancer research network UroCCR (NCT03293563; CNIL DR-2022-091). The primary endpoint was perioperative morbidity, assessed using the Clavien–Dindo classification. Secondary outcomes included Trifecta achievement, renal functional outcomes (pre- and 3-month postoperative eGFR, new-onset CKD, and AKI), and oncologic outcomes (disease-free survival [DFS], and overall survival [OS]). Overall, 212 patients underwent NSS for multiple ipsilateral renal tumors between June 2007 and July 2025 (146 RAPN, 66 OPN). After 1:1 matching for BMI, ASA score, and indication for NSS, 132 patients were analyzed (66 per group). RAPN was associated with shorter hospitalization (3.2 vs. 7.7 days, p < 0.001), fewer complications (6.1% vs. 21.2%, p = 0.02), and less frequent main renal artery clamping (51.5% vs. 86.4%, p < 0.001), despite longer operative and clamping times. Trifecta rates (50.8% vs. 61.9%, p = 0.29) and renal function at 3 months were comparable. At a median follow-up of 30.7 months, DFS and OS did not differ significantly between groups (p = 0.69). RAPN is a safe and effective alternative to OPN for multiple ipsilateral renal tumors, providing comparable oncologic and functional outcomes with reduced morbidity.